Titre
Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
McCloskey, E.V.
Auteure/Auteur
Vasikaran, S.
Auteure/Auteur
Cooper, C.
Auteure/Auteur
Contributrices/contributeurs
Hans, DB.
Cooper, C.
Baim, S.
Dawson-Hughes, B.
Kanis, JA.
Leslie, WD.
Luckey, MM.
Rizzoli, R.
Poiana, C.
Bilezekian, JP.
Papapoulos, SE.
McCloskey, EV.
Binkley, N.
Adachi, JD.
Baim, S.
Blank, RD.
Boonen, S.
Broy, SB.
Bruyere, O.
Chandran, M.
Cooper, C.
Dawson-Hughes, B.
Eastell, R.
Ensrud, K.
Dimai, HP.
Foldes, J.
Garnero, P.
Geusen, PP.
Griesmacher, A.
Hannan, MT.
Kanis, JA.
Kleerekoper, M.
Krieg, MA.
Langdahl, B.
Laster, A.
Leib, ES.
Masud, T.
McClung, M.
Morris, H.
Ortolani, S.
Saag, KG.
Siris, E.
Silverman, S.
Bobo Tanner, S.
Trenti, T.
Vasikaran, S.
Vestergaard, P.
Wahl, DA.
Michael Lewiecki, E.
Compston, JE.
Adachi, JD.
Adams, JE.
Adler, RA.
Bauer, DC.
Blake, GM.
Clark, P.
Diez-Perez, A.
Hans, DB.
Josse, RG.
Kanis, JA.
Kendler, DL.
Khan, AA.
Krieg, MA.
Leslie, WD.
Lorenc, RR.
Moayyeri, A.
Masri, BK.
Miller, PD.
Cauley, JA.
Fuleihan, el-HG.
Arabi, A.
Calderon, A.
Chen, Z.
Chionh, SB.
Curtis, J.
Danielson, ME.
Fujiwara, S.
Hanley, D.
Kroger, H.
Kung, A.
Lesnyak, O.
Looker, A.
Luckey, MM.
Mellstrom, D.
Nieves, J.
Pluskiewicz, W.
Rassi, RE.
Rizzoli, R.
Ragi-Eis, S.
Silverman, S.
Schott-Pethelaz, A.
Bilezekian, JP.
Papapoulos, SE.
Adachi, JD.
Blank, RD.
Chapurlat, R.
Chih-Hsing, W.
Czerwinski, E.
Perez, AD.
Dimai, HP.
Fuleihan, el-HG.
Fujiwara, S.
Ionescu, RM.
Kanis, JA.
McClung, M.
Stepan, J.
Ragi-Eis, S.
Saag, KG.
Schousboe, JT.
Yu, W.
Zerbini, C.
Brown, PD.
McKenney, P.
Johansson, H.
Nagy, J.
Oden, A.
Wahl, DA.
Groupes de travail
FRAX(®) Position Development Conference Members
Liens vers les personnes
Liens vers les unités
ISSN
1094-6950
Statut éditorial
Publié
Date de publication
2011
Volume
14
Numéro
3
Première page
220
Dernière page/numéro d’article
222
Langue
anglais
Notes
Publication types: Consensus Development Conference ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The best indirect evidence that increased bone turnover contributes to fracture risk is the fact that most of the proven therapies for osteoporosis are inhibitors of bone turnover. The evidence base that we can use biochemical markers of bone turnover in the assessment of fracture risk is somewhat less convincing. This relates to natural variability in the markers, problems with the assays, disparity in the statistical analyses of relevant studies and the independence of their contribution to fracture risk. More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®).
PID Serval
serval:BIB_D598908841E1
PMID
Date de création
2012-02-28T10:59:48.306Z
Date de création dans IRIS
2025-05-21T03:35:54Z